Through multidisciplinary coordination, effective communication, and a robust quality improvement initiative, we'll share invaluable insights, strategies, and patient-centered approaches that redefine ovarian cancer care. Gain firsthand knowledge from our panel of experts as they reveal lessons learned and experiences from participating in this quality improvement initiative. Discover how these insights have informed practice improvements, all while exploring the innovative Ovarian Quality of Care self-assessment tool, a valuable resource for cancer programs to enhance patient outcomes and drive excellence in ovarian cancer care.

This webinar will explore critical aspects of quality care in ovarian cancer treatment, exploring the journey from process optimization to enhancing overall patient outcomes. Our panel will illuminate the intricacies of ovarian cancer care, drawing from lessons learned across both phase one and two of the quality improvement initiative, and best practices in navigating the complexities of ovarian cancer care with a focus on continuous improvement.

Practical Insights on How to Improve Comprehensive Biomarker Testing in Advanced Non-Small Cell Lung Cancer

Explore opportunities to expand multidisciplinary care collaboration and coordination to improve care for patients with non-melanoma skin cancers.

T​his webinar will highlight how community cancer programs are using a new approach to optimize biomarker testing processes through the addition of a precision medicine steward.

Raise awareness among cancer programs of new treatment options for newly diagnosed patients with multiple myeloma ineligible for transplant.

This activity will provide guidance on how to develop practical biomarker testing protocols and identify appropriate therapeutics treatments for patients in all stages of mCRC.

This educational initiative will focus on multidisciplinary education surrounding TILs, with an emphasis on the importance of implementing clinical trials in the community setting.

Bispecific antibodies are an emerging class of novel immunotherapy agents that have led to major breakthroughs in treating hematologic malignancies—and have promising applications for solid tumors. Learn about the mechanism of bispecific antibodies, discover existing and emerging therapies, and hear about the administration of the first FDA-approved bispecific antibody for the treatment of malignancy, including challenges and opportunities.

Testing for measurable residual disease can shape treatment choices and affect overall outcomes for patients with B-cell acute lymphoblastic leukemia. Unfortunately, routine MRD testing is variable. This three-part webinar series is aimed at building capacity to implement, expand, and sustain MRD testing for patients with adult B-cell ALL at cancer programs and practices of all resource levels.